Company Active LTD

Company profile

Bactobio Ltd

Bactobio | London

At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.

CRN
12614308
Founded
2020
Age
6

Overview

Legal name
BACTOBIO LTD
Region
London
Registered address
UNIT 408 VOX STUDIOS
1-45 DURHAM STREET
LONDON
UNITED KINGDOM
SE11 5JH
Insolvency history
No

Latest accounts

Financial period: 1 Jun 2024 to 31 May 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
50

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

02 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

16 Apr
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUxNjY3Nzc2M2FkaXF6a2N4

Published 16 Apr 2026 14:03

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

19 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 May
2020

Incorporated

Inception

Company registered at Companies House

Public funding

12 awards
First funded
2021
Funded years
2021, 2022, 2023, 2024, 2025
Age at first award
0 years

Projects

2025 Collaborative R&D Lead participant

AI-guided antibiotic discovery for urinary tract infections

1 Aug 2025 to 31 Jan 2027

Awarded
£491,324
Total cost £701,891

Urinary tract infections (UTIs) are among the most common bacterial infections, impacting 50-60% of women during their lifetimes. UTIs are also the UK's leading infection in healthcare settings and responsible for 18,000 life-threatening bloodstream infections each year. ❯70% of UTIs are caused by _E. coli_: a WHO critical priority bacterial pathogen asso...

2024 Collaborative R&D Lead participant

Developing new bio-derived fungicides targeting Zymoseptoria tritici

1 Jul 2024 to 30 Jun 2027

Awarded
£1,628,455
Total cost £2,326,364

Modern farming relies on synthetic fungicides to support crop yields. Unfortunately, these chemicals are often associated with environmental and human health risks and are increasingly failing due to development of resistance. In the UK, wheat represents the primary arable grain crop, with an annual production of 15.5Mn tonnes and a market value of £1.2Bn...

2024 Collaborative R&D Lead participant

Genomic capture to combat the antimicrobial resistance crisis

1 Feb 2024 to 31 Jan 2025

Awarded
£348,092
Total cost £497,274

Antimicrobial resistance is a significant and growing threat to healthcare systems. ❯1.2Mn people die from drug-resistant infections every year, rising to 10Mn by 2050\. Resistance exists against all major antibiotic classes and no new classes have reached the clinic in 30 years. New drugs against deadly pathogens are needed now to ensure these infections...

2024 Grant for R&D Lead participant

Developing new microbe-derived fungicides against potato late blight

1 Jan 2024 to 30 Jun 2026

Awarded
£625,687
Total cost £893,839

Modern farming relies heavily on synthetic pesticides to secure crop yields. Synthetic fungicides come with environmental and health risks and are failing due to development of resistance. Treatment typically requires 1-5 applications per season, repeating at 10-14 day intervals during high risk periods. Potato late blight is the UK's most demanding plant...

2023 Collaborative R&D Lead participant

A heterologous expression toolkit for large-scale production of novel antimicrobials from diverse microbes

1 Sep 2023 to 30 Nov 2024

Awarded
£346,041
Total cost £494,344

New antimicrobials (antibiotics, antifungals and fungicides) are an urgent need. Each year ❯1.2Mn people die from drug-resistant infections and fungal crop diseases resulting in yield losses of up to 50% for major crops. For new antimicrobials to work against this backdrop of resistance, they must be chemically different from existing solutions, meaning t...

2023 Collaborative R&D Lead participant

High-throughput discovery of novel antibiotics against nontuberculous mycobacteria

1 Jun 2023 to 30 Nov 2024

Awarded
£349,781
Total cost £499,687

Nontuberculous mycobacteria(NTM) are a group of bacteria responsible for over 100,000 deadly lung infections annually. Infections predominantly impact immunocompromised patients and the cystic fibrosis(CF) community, with ❯10% of people with CF infected. High levels of intrinsic antimicrobial resistance and persistent infections have made these pathogens ...

2023 Collaborative R&D Lead participant

High-throughput discovery of novel antibiotics against resistant pathogens

1 Apr 2023 to 30 Sep 2024

Awarded
£493,417
Total cost £704,881

Introduction of antibiotics to the clinic less than 100 years ago extended life expectancies by ❯20 years and permitted development of medical interventions which were previously impossible. These treatments are now at risk from spreading drug resistance as bacteria constantly evolve to resist them, meaning our current repertoire is becoming increasingly ...

2022 Collaborative R&D Lead participant

Novel antifungal discovery from mining unexplored microbes

1 Dec 2022 to 31 May 2024

Awarded
£341,881
Total cost £488,402

Over 150Mn people are affected by severe fungal diseases each year with 1.7Mn deaths globally. The most severe infections include invasive aspergillosis (IA): a major healthcare-associated infection with mortality rates of up to 95%. Current therapeutic options for IA are limited to three drug classes with low efficacy, severe adverse effects, and high tr...

2022 Collaborative R&D Lead participant

Exploiting soil microbiomes for development of natural fungicides targeting P. infestans

1 May 2022 to 31 Oct 2023

Awarded
£227,223
Total cost £324,604

Potato late blight is one of the most damaging diseases facing England's crops. Untreated, it can devastate crops within 2 weeks of infection. Each year the disease is estimated to cause £3.5Bn in direct losses and control costs, including £800Mn in EU and UK alone. Managing blight requires the most fungicide applications of any crop in the UK, with growe...

2022 Collaborative R&D Lead participant

High-throughput identification of antibiotic compounds targeting P. aeruginosa

1 Apr 2022 to 31 Dec 2023

Awarded
£416,347
Total cost £594,782
2021 Collaborative R&D Lead participant

High-throughput discovery of natural product fungicides targeting Zymoseptoria tritici

1 Oct 2021 to 31 Mar 2023

Awarded
£237,477
Total cost £339,253

_Z. tritici_ is the most damaging wheat pathogen, responsible for yield losses of up to 50% annually. Farmers use up to 3 fungicide applications to manage this disease, but widespread use of chemical fungicides is causing pathogen resistance. We urgently need novel fungicides. This project will exploit Baccuico's library of natural compound-producing bact...

2021 Collaborative R&D Lead participant

Rapid discovery of novel antibiotics against A. baumannii

1 May 2021 to 31 Oct 2022

Awarded
£311,430
Total cost £444,900

Antimicrobial resistance (AMR) is a rapidly escalating healthcare crisis, estimated to cause 700,000 deaths globally per year, and predicted to rise to 10Mn by 2050, potentially a bigger killer than cancer and diabetes, combined. Treating AMR currently costs the NHS £180Mn per year. A combination of overuse and misuse of our current antibiotics has led to...

Product types

Collaborative R&D Grant for R&D